All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Oncosenx Inc., of Seattle, said it raised $3 million in pre-seed funding to advance its pipeline. The company is developing a selective tumor-killing platform with two main components: a proprietary lipid nanoparticle for cellular delivery and a selective DNA payload.